Antibodies are involved in the protective immunity induced in mice by <i>Schistosoma mansoni</i> schistosomula tegument (Smteg) immunization

Melo, Tatiane Teixeira de; Sena, I. C. de; Araújo, Neusa; Fonseca, Cristina Toscano

doi:10.1111/pim.12091

Cited by 20 publications

(19 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…De Melo et al [19] detected significant levels of antischistosomula tegument (Smteg) IgG antibodies in the sera of mice injected with Smteg compared to control group. This is also is in accordance with the results of de Melo et al [20] who transferred sera from mice immunized with Smteg or Smp-80 to a naïve recipient and that was able to induce partial protection against challenge infection. Our data allowed us to speculate that, PZQ administration enhanced the humoral response in naïve mice.…”

Section: Discussionsupporting

confidence: 92%

Immunostimulatory activity of schistosomula in mice

Aleem¹,

Elshaer²,

Afify³

et al. 2018

Russ Open Med J

View full text Add to dashboard Cite

Introduction -Our previous study cleared that both immunization with Egyptian Schistosoma mansoni schistosomula and therapy with praziquantel were able to induce significant levels of protection against re-infection as compared with immunization or treatment only. Aim -The current study aimed to evaluate the immunostimulatory activity of schistosomula in naïve mice post injection with schistosomula either alone or with praziquantel to answer the question: can schistosomula be used as immunoadjuvant? Material and Methods -Ten naïve mice were administered 3 doses of phosphate buffered saline. Ten mice injected with 500 schistosomula at day 0 and at 14 th day. Ten mice were administered praziquantel (PZQ) (250 mg/kg body weight).Ten mice injected with schistosomula at day 0 and at 14 th day and received PZQ. The levels of IgM and IgG against soluble egg antigen (SEA) and soluble worm antigen preparation (SWAP) were detected by ELISA. Immunophenotyping of mesenteric lymph nodes (MLN) lymphocytes and thymocytes were carried out. Results -IgM and IgG levels were significantly elevated in sera from mice injected with schistosomula alone or with PZQ or PZQ only. The mean percentage of MLN CD4 + , CD8 + T and B lymphocytes were increased but considered not significant. The MLN CD4 + /CD8 + T ratios were >1. The mean % of CD4 + and CD8 + thymocytes were increased and the CD4 + /CD8 + thymocytes ratios were >1. Conclusion -Immunostimulatory activity schistosomula was detected by enhancing Igs titers, stimulating the mean % of CD4 + , CD8 + T, B-MLN cells and thymocytes CD4 + , CD8 + T. CD4 + /CD8 + T cells ratios were >1 in MLN and thymus gland.

show abstract

Section: Discussionsupporting

confidence: 92%

Immunostimulatory activity of schistosomula in mice

Aleem¹,

Elshaer²,

Afify³

et al. 2018

Russ Open Med J

View full text Add to dashboard Cite

show abstract

“…These studies demonstrate that antibodies are involved in parasite elimination [19,23,24]. Our results show a vigorous humoral immune response, with significant levels of IgG, IgG1 and IgG2a, and IgE in infected/treated Balb/c mice immunized with rSm22.6 or rSm29 plus Freund’s adjuvant.…”

Section: Discussionsupporting

confidence: 60%

“…The schistosomula were cultured for 3 hours at 37°C in medium. Later, the schistosomula were incubated with immune sera and FITC-conjugated anti-mouse IgG, as described [19]. Briefly, schistosomula were washed three times with DMEM medium by centrifugation at 1800g/5 min.…”

Section: Methodsmentioning

confidence: 99%

Sm29, but Not Sm22.6 Retains its Ability to Induce a Protective Immune Response in Mice Previously Exposed to a Schistosoma mansoni Infection

et al. 2015

View full text Add to dashboard Cite

BackgroundA vaccine against schistosomiasis would have a great impact in disease elimination. Sm29 and Sm22.6 are two parasite tegument proteins which represent promising antigens to compose a vaccine. These antigens have been associated with resistance to infection and reinfection in individuals living in endemic area for the disease and induced partial protection when evaluated in immunization trials using naïve mice.Methodology/principals findingsIn this study we evaluated rSm29 and rSm22.6 ability to induce protection in Balb/c mice that had been previously infected with S. mansoni and further treated with Praziquantel. Our results demonstrate that three doses of the vaccine containing rSm29 were necessary to elicit significant protection (26%–48%). Immunization of mice with rSm29 induced a significant production of IL-2, IFN-γ, IL-17, IL-4; significant production of specific antibodies; increased percentage of CD4+ central memory cells in comparison with infected and treated saline group and increased percentage of CD4+ effector memory cells in comparison with naïve Balb/c mice immunized with rSm29. On the other hand, although immunization with Sm22.6 induced a robust immune response, it failed to induce protection.Conclusion/significanceOur results demonstrate that rSm29 retains its ability to induce protection in previously infected animals, reinforcing its potential as a vaccine candidate.

show abstract

“…Sera obtained from donor immunized mice and baboons have been shown to protect recipients against subsequent schistosome challenge when passively transferred (Byram et al 1979; Doenhoff et al 1979; Mangold and Dean 1986; Melo et al 2014; Torben et al 2011). Studies utilizing schistosome non- and/or semi-permissive host such as rats have shown that resistance to schistosome infections as well as mechanism of schistosome killing are almost entirely humoral mediated by high IgG antibodies (Knopf et al 1977; Wilson et al 2008).…”

Section: Discussionmentioning

confidence: 99%

Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium

et al. 2017

View full text Add to dashboard Cite

Schistosomiasis remains a major global health problem. Despite large-scale schistosomiasis control efforts, clear limitations such as possible emergence of drug resistance and re-infection rates, highlight the need for an effective schistosomiasis vaccine. Schistosoma mansoni large subunit of calpain (Sm-p80)-based vaccine formulations have shown remarkable efficacy in protecting against S. mansoni challenge infections in mice and baboons. In this study, we evaluated the cross-species protective efficacy of Sm-p80 vaccine against S. japonicum and S. haematobium challenge infections in rodent models. We also elucidated the expression of Sm-p80 and Sm-p80 ortholog proteins in different developmental stages of S. mansoni, S. haematobium and S. japonicum. Immunization with Sm-p80 vaccine reduced worm burden by 46.75% against S. japonicum challenge infection in mice. DNA-prime/protein boost (1+1 dose administered on a single day) resulted in 26.95% reduction in worm burden in S. haematobium-hamster infection/challenge model. A balanced Th1 (IFN-γ, TNF-α, IL-2 and IL-12) and Th2 (IL-4, IgG1) type of responses were observed following vaccination in both S. japonicum and S. haematobium challenge trials and these are associated with the prophylactic efficacy of Sm-p80 vaccine. Immunohistochemistry demonstrated that Sm-p80/Sm-p80 ortholog proteins are expressed in different life cycle stages of the three major human species of schistosomes studied. The data presented in this study reinforce the potential of Sm-p80-based vaccine for both hepatic/intestinal and urogenital schistosomiasis occurring in different geographical areas of the world. Differential expression of Sm-p80/Sm-p80 protein orthologs in different life cycle makes this vaccine potentially useful in targeting different levels of infection, disease and transmission.

show abstract

Antibodies are involved in the protective immunity induced in mice by Schistosoma mansoni schistosomula tegument (Smteg) immunization

Cited by 20 publications

References 16 publications

Immunostimulatory activity of schistosomula in mice

Immunostimulatory activity of schistosomula in mice

Sm29, but Not Sm22.6 Retains its Ability to Induce a Protective Immune Response in Mice Previously Exposed to a Schistosoma mansoni Infection

Cross-species prophylactic efficacy of Sm-p80-based vaccine and intracellular localization of Sm-p80/Sm-p80 ortholog proteins during development in Schistosoma mansoni, Schistosoma japonicum, and Schistosoma haematobium

Contact Info

Product

Resources

About